Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients

Journal of Translational Medicine

Volumn 10, Issue 1, 2012, Pages

  Sigalotti, Luca ^a   Covre, Alessia ^a,b   Fratta, Elisabetta ^a   Parisi, Giulia ^a,b   Sonego, Paolo ^c   Colizzi, Francesca ^a   Coral, Sandra ^a   Massarut, Samuele ^a   Kirkwood, John M ^d   Maio, Michele ^a,b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b UNIVERSITY HOSPITAL OF SIENA   (Italy)

^c CBM scrl Genomics Area Science Park   (Italy)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

Hypermethylation; Immunotherapy; Prognosis; Prognostic signature; Whole genome methylation profiling

Indexed keywords

ANTINEOPLASTIC AGENT; GENOMIC DNA;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; DNA METHYLATION; FEMALE; HUMAN; HUMAN CELL; MALE; MELANOMA; OVERALL SURVIVAL; PREDICTION; PROGNOSIS;

ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; DNA METHYLATION; DNA PRIMERS; FEMALE; GENOME; HUMANS; MALE; MELANOMA; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS;

EID: 84865662831     PISSN: None     EISSN: 14795876     Source Type: Journal    
DOI: 10.1186/1479-5876-10-185     Document Type: Article

References (21)

1. MacKie RM, Hauschild A, Eggermont AM. Epidemiology of invasive cutaneous melanoma. Ann Oncol 2009, 20(6):1-7.
2. Balch CM, Buzaid AC, Soong SJ, Atkins MB, Cascinelli N, Coit DG, Fleming ID, Gershenwald JE, Houghton A, Kirkwood JM, et al. Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 2001, 19(16):3635-3648.
3. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, Buzaid AC, Cochran AJ, Coit DG, Ding S, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol 2009, 27(36):6199-6206. 10.1200/JCO.2009.23.4799, 2793035, 19917835.
4. Jennings L, Murphy GM. Predicting outcome in melanoma: where are we now?. Br J Dermatol 2009, 161(3):496-503. 10.1111/j.1365-2133.2009.09324.x, 19624540.
5. Sigalotti L, Covre A, Fratta E, Parisi G, Colizzi F, Rizzo A, Danielli R, Nicolay HJ, Coral S, Maio M. Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. J Transl Med 2010, 8:56. 10.1186/1479-5876-8-56, 2901206, 20540720.
6. Esteller M. Epigenetics in cancer. N Engl J Med 2008, 358(11):1148-1159. 10.1056/NEJMra072067, 18337604.
7. Lahtz C, Stranzenbach R, Fiedler E, Helmbold P, Dammann RH. Methylation of PTEN as a prognostic factor in malignant melanoma of the skin. J Invest Dermatol 2010, 130(2):620-622. 10.1038/jid.2009.226, 19798057.
8. You Y, Ma L, You M, Li X, Wang S, Li H, Wu D, Yang H, Li ZY. TSLC1 gene silencing in cutaneous melanoma. Melanoma Res 2010, 20(3):179-183.
9. Tanemura A, Terando AM, Sim MS, van Hoesel AQ, de Maat MF, Morton DL, Hoon DS. CpG island methylator phenotype predicts progression of malignant melanoma. Clin Cancer Res 2009, 15(5):1801-1807. 10.1158/1078-0432.CCR-08-1361, 2703821, 19223509.
10. Sigalotti L, Fratta E, Bidoli E, Covre A, Parisi G, Colizzi F, Coral S, Massarut S, Kirkwood JM, Maio M. Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. J Transl Med 2011, 9:78. 10.1186/1479-5876-9-78, 3123580, 21615918.
11. Altomonte M, Gloghini A, Bertola G, Gasparollo A, Carbone A, Ferrone S, Maio M. Differential expression of cell adhesion molecules CD54/CD11a and CD58/CD2 by human melanoma cells and functional role in their interaction with cytotoxic cells. Cancer Res 1993, 53(14):3343-3348.
12. Fratta E, Sigalotti L, Colizzi F, Covre A, Nicolay HJ, Danielli R, Fonsatti E, Altomonte M, Calabro L, Coral S, et al. Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. J Cell Physiol 2010, 223(2):352-358.
13. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics 2002, 18(11):1427-1431. 10.1093/bioinformatics/18.11.1427, 12424112.
14. Kaplan EL, Meier P. Nonparametric Estimation from Incomplete Observations. J Am Statistical Association 1958, 53(282):457-481.
15. Cox DR. Regression models and life-tables (with discusssion). J Roy Statist Soc B 1972, 34:187-220.
16. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci U S A 2002, 99(10):6567-6572. 10.1073/pnas.082099299, 124443, 12011421.
17. Teodoridis JM, Hardie C, Brown R. CpG island methylator phenotype (CIMP) in cancer: causes and implications. Cancer Lett 2008, 268(2):177-186. 10.1016/j.canlet.2008.03.022, 18471961.
18. Shen L, Catalano PJ, Benson AB, O'Dwyer P, Hamilton SR, Issa JP. Association between DNA methylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil based chemotherapy. Clinical cancer research: an official journal of the American Association for Cancer Research 2007, 13(20):6093-6098.
19. Sigalotti L, Fratta E, Coral S, Cortini E, Covre A, Nicolay HJ, Anzalone L, Pezzani L, Di Giacomo AM, Fonsatti E, et al. Epigenetic drugs as pleiotropic agents in cancer treatment: biomolecular aspects and clinical applications. J Cell Physiol 2007, 212(2):330-344. 10.1002/jcp.21066, 17458893.
20. Van der Auwera I, Yu W, Suo L, Van Neste L, van Dam P, Van Marck EA, Pauwels P, Vermeulen PB, Dirix LY, Van Laere SJ. Array-based DNA methylation profiling for breast cancer subtype discrimination. PLoS One 2010, 5(9):e12616. 10.1371/journal.pone.0012616, 2935385, 20830311.
21. Tremante E, Ginebri A, Lo Monaco E, Frascione P, Di Filippo F, Terrenato I, Benevolo M, Mottolese M, Pescarmona E, Visca P, et al. Melanoma molecular classes and prognosis in the postgenomic era. Lancet Oncol 2012, 13(5):e205-e211. 10.1016/S1470-2045(12)70003-7, 22554548.